Skip to main content
Premium Trial:

Request an Annual Quote

Labec Pharma to Distribute Interleukin Genetics' Test

NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has signed up Labec Pharma of Madrid to distribute its genetic test for heart attack risk in Spain and Portugal.

The Cardio Health test identifies multiple genetic variations that can lead to overproduction of certain chemicals that can cause inflammation, and can indicate "a statistically significant risk" for heart attack, the Waltham, Mass.-based company said.

Under the agreement, Interleukin Genetics will receive royalties and processing fees on the sale of each test, which will be processed at Interleukin's US lab.

Labec Pharma CEO Javier de Echevarria said in a statement that the genetic test has been "validated by two independent clinical studies that demonstrated its ability to identify individuals with significantly elevated risk of heart attack."